NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Oct 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
5/8 — Partial
Priority Review
VEKLURY (remdesivir) by Gilead Sciences. Approved for sars-cov-2 nucleotide analog rna polymerase inhibitor [epc]. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEKLURY (remdesivir) is a small-molecule nucleotide analog that inhibits SARS-CoV-2 RNA polymerase, approved in October 2020 for COVID-19 and also indicated for Ebola virus and RSV infections. Administered intravenously, it works by interfering with viral replication machinery. The drug represents a critical pandemic-era therapeutic option for hospitalized patients.
$0.583MPart D
Peak15.6 years to LOEProduct is at peak commercial maturity with modest Medicare utilization; commercial teams focus on maintaining market position and managing payer relations in a declining pandemic environment.
Mechanism of Action
Pharmacologic Class:
SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Started Dec 2025
60 enrolled
Hematopoietic and Lymphatic System NeoplasmAutoimmune DiseaseRespiratory Syncytial Virus Infection
Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients
Started Sep 2025
15 enrolled
COVID - 19Renal TransplantSARS CoV 2 Infection
OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA
Started Aug 2021
87 enrolled
Duration of HospitalizationClinical Manifestation of COVID-19
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Started Apr 2021
87 enrolled
Covid19
PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US
Started Mar 2021
54 enrolled
COVID-19
Worked on VEKLURY at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.